Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Chartwell Pharmaceuticals Carmel LLC
EIR
•Chartwell Pharmaceuticals Carmel LLC•November 2, 2015

Chartwell Pharmaceuticals Carmel LLC – FDA EIR, Nov 2, 2015

Record Details

An FDA inspection of Silarx Pharmaceuticals, Inc. in Carmel, NY, was conducted from October 19 to November 2, 2015. This comprehensive inspection, guided by CPGM 7356.002 for drug manufacturing and CPGM 7352.832 for Pre-Approval Inspections (specifically ANDA 207236 for Memantine HCl Tablets), assessed the company's compliance with current Good Manufacturing Practices (cGMP). The inspection identified six significant observations, detailed in an FDA-483. Key issues included: inadequate review of executed batch records for accuracy, a lack of authority within the quality control unit to assure production record integrity, and deficiencies in microbiological testing media preparation, storage, and growth promotion testing. Furthermore, Silarx was cited for not conducting stability chamber mapping studies under full-load conditions, insufficient calibration and qualification of manufacturing and packaging equipment, and inadequate cleaning validation studies (a recurring issue from a previous inspection). Specifically for ANDA 207236, discrepancies were found between documented and actual packaging equipment, and critical equipment was uncalibrated for in-process checks. At the closeout meeting, Silarx management acknowledged the observations and provided a commitment letter, promising a written response within 15 business days. Consequently, the FDA recommended a "Withhold" for ANDA 207236, pending satisfactory resolution of the identified deficiencies and submission of corrective actions.

Company
Chartwell Pharmaceuticals Carmel LLC
Inspection date
November 2, 2015
Product type
RX (Prescription)
Office
New York District Office
People
  • Rohit Desai (company_representative)
  • Mahendra Dedhiya (company_representative)
  • Mindy M. Chou
  • Daniel Bitler (recipient)
  • Helen B. Ricalde (Director, Team Biologics Staff)
View Company Profile

ID · 3743fc5f-65f0-404f-8833-80f2081e18ea

Other documents for Chartwell Pharmaceuticals Carmel LLC
  • 483 - 2024-12-20December 20, 2024
  • 483 - 2024-01-11January 11, 2024
  • 483 - 2022-10-06October 6, 2022
  • 483 - 2019-12-16December 16, 2019
  • EIR - 2019-12-16December 16, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Chartwell Pharmaceuticals Carmel LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.